Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Policy Power Challenged In House Questions On Untitled Letters

This article was originally published in The Tan Sheet

Executive Summary

Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee examines whether FDA use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.

You may also be interested in...



FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.

FDA Off-Label Citations Disappear In Post-Caronia Enforcement Letters

Office of Prescription Drug Promotion letters post-Caronia fail to cite off-label promotion, in contrast to previous years when about one-third to one-half of warning and untitled letters scolded companies for off-label violations.

Warning For Facebook “Likes” Reflects FDA Social Media Approach

FDA is revealing its views on social media use through individual enforcement actions and provisions in disparate guidances, in the absence of issuing an overarching guidance. A recent warning letter sheds light on the agency’s view of “liking” something on Facebook.

Related Content

Topics

UsernamePublicRestriction

Register

PS107710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel